Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.

O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM

The Journal of clinical endocrinology and metabolism1 May 1993Cited by 128 (Europe PMC)

PMID8496328DOI10.1210/jcem.76.5.8496328PepBankPUB-08496328

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, proximal forearm BMC did not change after 6 months of GH.
In plain wordsIn GH-deficient adults, forearm cortical bone mineral content did not change after 6 months of GH.
Peptide
HGH (somatotropin)
Outcome
No significant changeProximal forearm BMC at 6 months
Study
n = 12
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Source sentences
Summary
Proximal forearm (cortical) BMC showed no change after 6 months of GH replacement, but there was a significant increase of 0.06 g/cm after 12 months of GH replacement (from 1.38 +/- 0.04 to 1.44 +/- 0.04 g/cm; n = 12; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632802
02HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, proximal forearm BMC increased significantly by 0.06 g/cm after 12 months of GH.
In plain wordsIn GH-deficient adults, forearm cortical bone mineral content increased from baseline after 12 months of GH.
Peptide
HGH (somatotropin)
Outcome
IncreaseProximal forearm BMC at 12 months
Study
n = 12
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Measurements
BMC increase
0.06 g/cm
12 months
Baseline BMC
1.38 g/cm
baseline
BMC
1.44 g/cm
12 months
Source sentences
Summary
Proximal forearm (cortical) BMC showed no change after 6 months of GH replacement, but there was a significant increase of 0.06 g/cm after 12 months of GH replacement (from 1.38 +/- 0.04 to 1.44 +/- 0.04 g/cm; n = 12; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632803
03HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, distal forearm BMC increased significantly from 1.46 to 1.52 g/cm during GH treatment.
In plain wordsIn GH-deficient adults, GH increased distal forearm bone mineral content from baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseDistal forearm BMC
Study
n = 12
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Measurements
Baseline BMC
1.46 g/cm
baseline
BMC
1.52 g/cm
during study
Source sentences
Summary
Distal forearm (cortical and trabecular) BMC also increased significantly during the study period from 1.46 +/- 0.04 g/cm to 1.52 +/- 0.05 g/cm; n = 12, P < 0.05.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632804
04HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, spinal trabecular bone density increased after 6 months of GH, and the increment remained at 1 yr.
In plain wordsIn GH-deficient adults, GH increased spinal bone density from baseline, and the increase remained at 1 yr.
Peptide
HGH (somatotropin)
Outcome
IncreaseSpinal trabecular bone mineral density
Study
n = 11
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Measurements
Density increase
7.8 g/L
6 months
Baseline density
151.7 g/L
baseline
Density
159.5 g/L
6 months
Density
160.7 g/L
1 yr
Source sentences
Summary
In the treatment cohort, quantitative computed tomography spinal trabecular bone mineral density increased by 7.8 g/L after 6 months of GH replacement (mean +/- SEM, 151.7 +/- 6.0 vs. 159.5 +/- 5.9 g/L; n = 11; P < 0.01), and this increment was maintained at 1 yr (160.7 +/- 6.3 g/L).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632801
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, midthigh muscle area increased during active GH treatment.
In plain wordsIn GH-deficient adults, thigh muscle area increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseMidthigh muscle area
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Source sentences
Summary
Midthigh muscle and fat cross-sectional area increased and decreased, respectively, during the active treatment phase.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632805
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, midthigh fat area decreased during active GH treatment.
In plain wordsIn GH-deficient adults, thigh fat area decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseMidthigh fat area
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
0.125 IU/kg.week for the first 4 weeks and subsequently 0.25 IU/kg.week · subcutaneous · 1 yrAs given in this study (human).
Source sentences
Summary
Midthigh muscle and fat cross-sectional area increased and decreased, respectively, during the active treatment phase.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 12 adults (10 males and 2 females) with isolated GH deficiency were treated with GH as a single daily sc injection (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week) for 1 yr in a double blind, placebo-controlled manner.
Report a problemFND-0849632806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.